[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Given the clinical picture \u2013 HIV infection with a low CD4 count, neurological symptoms (headaches, blurred vision, confusion, ataxia, memory impairment), CSF findings (lymphocytic pleocytosis, EBV positivity), and MRI findings (solitary, ring-enhancing lesion in the corpus callosum) \u2013 the most likely diagnosis is **Progressive Multifocal Leukoencephalopathy (PML)**.\n\nWhile EBV is detected in CSF, it\u2019s often associated with PML in immunocompromised individuals, not necessarily primary EBV encephalitis. The lesion location and MRI characteristics are also highly suggestive of PML.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "That's a good question for a new clinician to ask!\n\n**Enfuvirtide** is the antiretroviral medication that acts on the gp41 subunit of the HIV envelope glycoprotein. It's a fusion inhibitor.\n\nHowever, it's not typically a first-line treatment due to its administration route (subcutaneous injection) and tolerability issues. Current guidelines favor integrase inhibitors, and certain NRTIs as initial therapy.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV-1 detection test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "Acute HIV infection. \n\nA recent positive test with these symptoms, and a relatively normal CD4 count, points to primary/acute infection \u2013 the initial stage after exposure.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9\u00b0F (38.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. What is the mechanism of action of the most appropriate drug for managing this patient\u2019s condition?",
    "answer": "Given the patient's presentation \u2013 fever, night sweats, productive cough, low CD4 count, cavitary lesions on chest X-ray, and the presence of partially acid-fast gram-positive branching rods in the BAL \u2013 the most likely diagnosis is *Nocardia* pneumonia. \n\nThe most appropriate drug is typically **sulfonamides** (like trimethoprim-sulfamethoxazole - TMP-SMX).\n\n**Mechanism of Action:** Sulfonamides are structural analogs of para-aminobenzoic acid (PABA). They competitively inhibit dihydropteroate synthase, an enzyme crucial in bacteria's folate synthesis pathway. This ultimately blocks the production of tetrahydrofolic acid, essential for bacterial DNA and RNA synthesis, thus inhibiting bacterial growth.",
    "true_answer": "The mechanism of action of the most appropriate drug to manage this patient's condition is inhibition of bacterial folic acid synthesis."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "That's a good research direction. The most likely target for a broadly neutralizing antibody (the goal here, given the desire for \"more potent\") would be **the CD4 binding site (CD4bs) on the gp120 protein.** \n\nHere's why:\n\n*   **Neutralization:** Antibodies that bind to the CD4bs can prevent the virus from attaching to the CD4 receptor on host cells, thus neutralizing it.\n*   **Conservation:** While HIV is highly variable, the CD4bs is relatively conserved as mutations here often reduce viral entry efficiency.\n*   **Broadly Neutralizing:** Antibodies to this site are more likely to be broadly neutralizing, effective against multiple HIV strains.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "That presentation strongly suggests *Aspergillus* species. The fibrocavitary lesion, hemoptysis, and acute-angle branching septate hyphae on biopsy are classic findings in pulmonary aspergillosis, particularly in an immunocompromised host like a patient with HIV.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "Valganciclovir, combined with zidovudine, carries a significant risk of **myelosuppression** \u2013 specifically, neutropenia and anemia. Both drugs can independently cause bone marrow suppression, and the combination increases this risk substantially.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "That's a very common and valid concern. The most appropriate test immediately after delivery would be **HIV-1 DNA PCR (polymerase chain reaction)**. \n\nHere's why:\n\n*   **Early Detection:** PCR detects the virus itself, not antibodies. Maternal antibodies cross the placenta, so an antibody test on the baby wouldn't indicate *active* infection, only exposure.\n*   **Timing:** PCR can detect the virus within the first few days of life, much earlier than antibody tests.\n*   **Specificity:** It\u2019s the standard for diagnosing HIV in infants.\n\nOther tests (like antibody testing) have a role later, but PCR is key initially.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "This is a complex ethical and legal situation. The most appropriate next step is **to strongly counsel the patient about the legal and ethical obligations regarding partner notification, and the potential legal ramifications of not disclosing his HIV status to his wife, who is at risk.**\n\nHere's why, and what follows:\n\n*   **Duty to Warn:** Many jurisdictions have laws regarding the duty to warn individuals at risk of contracting a life-threatening communicable disease.\n*   **Patient Confidentiality vs. Public Health:** While patient confidentiality is paramount, it is *not* absolute. It can be overridden by a clear and present danger to a third party.\n*   **Physician-Patient Relationship with Both:** You have a pre-existing relationship with the wife, increasing your responsibility.\n*   **Encourage Voluntary Disclosure:** The physician should strongly encourage the patient to disclose his status to his wife himself. Offer support and resources to facilitate this conversation.\n*   **Legal Consultation:** The physician *must* consult with legal counsel to understand the specific laws in their jurisdiction and navigate the appropriate course of action.\n\n\n\n**Do not** breach confidentiality without legal guidance. Simply telling the wife would be a breach of confidentiality with the patient and could have legal consequences *unless* legally mandated.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Given the clinical presentation \u2013 acute epigastric pain radiating to the back, nausea, vomiting, elevated amylase and lipase, and CT findings of pancreatitis \u2013 the most likely etiology is **acute pancreatitis**. \n\nWhile her HIV infection is part of her medical history, it's not the *most* likely immediate cause. However, it's important to consider HIV and its treatment as potential contributing factors (see below).\n\n**Important Considerations:**\n\n*   **Medication-induced:** Some HIV medications (like certain protease inhibitors or didanosine) can rarely cause pancreatitis. We need to determine *which* HIV medications she is taking.\n*   **HIV-related:** While less common now with modern ART, HIV itself can be associated with pancreatitis, particularly with lower CD4 counts.\n*   **Gallstones:** Though the gallbladder appears normal on imaging, microlithiasis isn't always visible.\n*   **Alcohol use:** Moderate alcohol use is a risk factor.\n*   **Diabetes:** Diabetes is also a risk factor for pancreatitis.",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " A 28-year-old primigravid woman at 38 weeks' gestation is brought to the emergency department in active labor. She has not had regular prenatal care. She has a history of HIV infection but is not currently on antiretroviral therapy. Her previous viral load is unknown. Treatment with intravenous zidovudine is begun to reduce perinatal transmission of the virus. What biological process is most likely disrupted by this drug\u2019s action mechanism?",
    "answer": "That's a good question to consider in this clinical scenario.\n\nZidovudine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI). Therefore, the biological process most disrupted by its action is **reverse transcription** \u2013 the process by which HIV converts its RNA genome into DNA. \n\nEssentially, AZT acts as a faulty building block, halting the creation of viral DNA.",
    "true_answer": " Zidovudine affects elongation of viral DNA by inhibiting the viral reverse transcriptase enzyme."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "That's a good question, and an area of active research. Here's a brief overview:\n\n**Latent HIV-1:** Studies show distinct DNA methylation patterns in latently infected cells (the reservoir) compared to uninfected cells. Generally, there's *hyper*methylation of the HIV-1 provirus \u2013 meaning more methylation \u2013 which contributes to transcriptional silencing and reservoir maintenance. Specific methylation changes are seen in the LTR region.\n\n**Active Infection:** During active infection, methylation patterns are more dynamic. Initially, you might see *hypo*methylation of the provirus, allowing for viral replication. As infection becomes chronic, methylation patterns can vary depending on the cell type and stage of disease. \n\nEssentially, methylation is a key epigenetic mechanism influencing HIV persistence and gene expression. It's a complex topic, and research is ongoing to understand how to manipulate these patterns for a cure.",
    "true_answer": "DNA methylation is correlated with and functionally linked to HIV-1 pathogenesis and latency. In active infection, HIV-1 infection is associated with global changes in host cell DNA methylation patterns, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]